Springer CME Symposium
ADCs a new era in myeloma therapy
Thursday May 11, 2023 – 08:30-10:00 CEST
Agenda
| 08:30-08:35 | Welcome and introduction Mohamad Mohty |
| 08:35-08:55 | From alkylating agents to immunotherapy: 50 years of progress Jean-Luc Harousseau |
| 08:55-09:15 | Sequencing immunotherapies: where do we stand? María-Victoria Mateos |
| 09:15-09:35 | ADCs for relapsed/refractory myeloma Rakesh Popat |
| 09:35-09:45 | Discussion and Q&A All |
| 09:45-09:55 | Close Mohamad Mohty |
Learning Objectives
At the end of the symposium, participants will be able to:
- Describe the therapeutic changes in the treatment landscape of MM and the advantages brought by new immunotherapy agents
- Discuss sequencing strategies and factors influencing treatment selection for subsequent treatment lines
- Analyze available data on ADCs in relapsed MM and strategies to manage AEs associated with these agents
ADCs = antibody-drug conjugates, AEs = adverse events, MM = multiple myeloma
Faculty
Dr Mohamad Mohty
Sorbonne University, France
Dr Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of the EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and board member of the EBMT and the Intergroupe Francophone du Myelome (IFM).
In addition to publishing more than 900 peer-reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, Dr Mohty also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International.
Jean-Luc Harousseau
Institut de cancerologie de l’ouest, France
Jean-Luc Harousseau is Professor of Hematology at the University of Nantes in France. He was Chairman of the French National Authority for Health (HAS) from February 2011 to January 2016 and Chair of its Economic and Public Health Evaluation Committee from February 2014 to January 2016. He headed the Department of Clinical Haematology in Nantes University Hospital for 24 years and was Director of the Cancer Center René Gauducheau in Nantes from October 2008 to January 2011.
In his previous positions, he has been a member of the Scientific Advisory Board of the French National Cancer Institute and President of the Clinical Research in Oncology National Committee from October 2008 to January 2011.
His areas of research interest concern the therapy of acute myeloid leukemia and for the last thirty years Multiple Myeloma. He received the 2005 Waldenström Award and the 2009 Robert Kyle Award for his scientific contribution in the field of Multiple Myeloma. Professor Harousseau has contributed to more than 500 peer-reviewed publications.
María-Victoria Mateos
University Hospital of Salamanca, Spain
Dr. María-Victoria Mateos, MD, PhD, is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit.
She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials especially in the setting of transplant ineligible and smouldering myeloma and these trials have profoundly influenced current options for the management of these patient populations.
She has published over 350 papers in international journals with a H index of 96 and 74 since 2015.
Rakesh Popat
University College London Hospitals NHS Foundation Trust, England
He graduated from Guy’s and St. Thomas’ Medical School in London and trained in haematology at St. Bartholomew’s and the Royal London Hospitals. During this time he completed a PhD in novel treatments for myeloma and was awarded a fellowship to attend the Dana Farber Cancer Institute, Boston USA as part of this.
He has particular experience with novel treatments including immunotherapies such as CAR-T cell therapy and new antibody approaches. At University College Hospital, he leads the myeloma clinical trials programme, is the Cancer lead at the NIHR UCLH Clinical Research Facility and trials co-lead for the UCL Experimental Cancer Medicine Centre.
Dr Popat is the Chair of the UK Myeloma Research Alliance, NCRI Myeloma working group, is on the executive board of the UK Myeloma Society, the Young Board of the European Myeloma Network and a member of the International Myeloma Working Group. He is the Chief Investigator for a number of relapsed myeloma studies and the Principal Investigator for the NIHR Health Informatics Collaborative Myeloma database.
Accreditation
This symposium has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH) CME Unit. The EBAH-CME Unit has approved this educational activity for:
1 EBAH credit points
Each physician should only claim credits for time that she/he actually spent in the educational activity.
All participants may print a European Board for Accreditation in Hematology (EBAH) CME certificate indicating the number of EBAH-CME Credit Points awarded, directly from the system on the CME section of the EBAH website at (www.ebah.org).
How to collect your EBAH-CME credit points:
- Visit our website: ebah.org
- Create a professional account: simple and free of cost
- Complete the short evaluation form at the end of the symposium and select the option to receive CME credits
Within the EBAH-CME system you can:
- Print your EBAH-CME certificates
- Review and manage your personal account
- Search for accredited events based on the European Hematology Curriculum
For further assistance please contact:
EBAH
Email: info@ebah.org
Tel: +31 70 3020 099
Funding
This program is made possible thanks to an educational grant received from GlaxoSmithKline.